Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced ...

We determined the incidence of severe bleeding from gastric antral vascular ectasia (GAVE) after myeloablative hematopoietic cell transplant and the outcomes after treatment with endoscopic ...

Data consistently shows that exercise is key to well-being in nearly every facet of life; its positive impact is unquestioned. But what about when people, perhaps not by choice, need to sit on the ...

Spurred by a positive clinical trial readout recently, Xeltis has raised €47.5m ($55.1m) to advance commercialisation efforts ...

Final 12-month data from the EXACT trial demonstrates safety and efficacy results for a vascular endothelial growth factor (VEGF) gene therapy treatment for patients who have advanced coronary artery ...

Lorem Vascular agreed to pay up to $531 million for a 30-year exclusive license to commercialize Cytori Cell Therapy for the cardiovascular, renal, and diabetes markets in China, Hong Kong, Malaysia, ...

DARIEN, Conn.--(BUSINESS WIRE)--Dr. Paul Gagne and the research team at Vascular Breakthroughs, LLC, and Vascular Care Connecticut have reached a key clinical development milestone in their ...

Researchers from the Centenary Institute have discovered a potential new therapy for cerebral cavernous malformations (CCMs), a devastating disease that often affects young people and can result in ...

Rather than destroying or removing defective veins, it is possible to repair them by using a sheath. They are thus saved for later use as a bypass. In cases of severe varicose vein disease, dilated ...